These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16878453)

  • 21. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The virucidal effect of platelet concentrates: preliminary study and first conclusions.
    Maurice A; Marchand-Arvier M; Edert D; Le Faou A; Gondrexon G; Vigneron C
    Platelets; 2002 Jun; 13(4):219-22. PubMed ID: 12189023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Viral attenuation of labile blood products].
    Folléa G; Hervé P; Andreu G; Bidet JM; Boudard D; Dazey B; Noël L; Piquet Y
    Transfus Clin Biol; 1996; 3(2):113-23. PubMed ID: 8963430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivation of microbial contaminants of blood components.
    AuBuchon JP; Dodd RY
    Clin Lab Med; 1992 Dec; 12(4):787-803. PubMed ID: 1286565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer.
    Corbin F
    Int J Hematol; 2002 Aug; 76 Suppl 2():253-7. PubMed ID: 12430933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Labile blood products and their preparation].
    Chabanel A; Folléa G
    Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
    Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
    Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-time polymerase chain reaction in transfusion medicine: applications for detection of bacterial contamination in blood products.
    Dreier J; Störmer M; Kleesiek K
    Transfus Med Rev; 2007 Jul; 21(3):237-54. PubMed ID: 17572262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet transfusion: products, indications, dose, threshold and efficacy].
    Andreu G; Vasse J; Tardivel R; Semana G
    Transfus Clin Biol; 2009 May; 16(2):118-33. PubMed ID: 19443257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate].
    Spannagl M; Joch Ch; Heindl B
    Hamostaseologie; 2006 Aug; 26(3 Suppl 1):S36-40. PubMed ID: 16953291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?
    Hellstern P
    Transfus Apher Sci; 2008 Aug; 39(1):69-74. PubMed ID: 18583192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
    Sawyer L; Hanson D; Castro G; Luckett W; Dubensky TW; Stassinopoulos A
    Transfusion; 2007 Jun; 47(6):1062-70. PubMed ID: 17524098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.
    Trannoy LL; Terpstra FG; de Korte D; Lagerberg JW; Verhoeven AJ; Brand A; van Engelenburg FA
    Vox Sang; 2006 Aug; 91(2):111-8. PubMed ID: 16907871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk management in transfusion after the HIV blood contamination crisis in France: the impact of the precautionary principle.
    Hergon E; Moutel G; Duchange N; Bellier L; Rouger P; Hervé C
    Transfus Med Rev; 2005 Oct; 19(4):273-80. PubMed ID: 16214016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of riboflavin for the inactivation of pathogens in blood products.
    Goodrich RP
    Vox Sang; 2000; 78 Suppl 2():211-5. PubMed ID: 10938955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma.
    Solheim BG; Chetty R; Flesland O
    Curr Opin Hematol; 2008 Nov; 15(6):612-7. PubMed ID: 18832933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.